Kornimate/medical-research-clean huggingface dataset:
a mindfulness-based self-compassion program

Conditions: Breast Cancer Survivor

Summary: the purpose of this study is a pre-test-post-test, randomized controlled experimental study with a control group, planned to examine the effect of the mindfulness-based self-compassion program applied on women with breast cancer on spiritual well-being and self-compassion levels.

the research was designed experimentally. the research will be conducted between february 2025 and april 2025 with female patients diagnosed with breast cancer who were treated in the oncology service of cumhuriyet university faculty of medicine hospital in sivas-central province in the middle of turkey and who meet the inclusion criteria. the study will be carried out face to face after obtaining the necessary institutional permissions. participants to be included in the research will be included in the sample by taking into account the inclusion criteria at each stage. after the subject, purpose and method of the study are explained to the participants to be included in the study, they will be asked to fill out the informed consent form. participants will then be divided into intervention and control groups by simple randomization method. before the intervention, an information form, self-compassion scale and spiritual well-being scale (facit-sp-12) will be applied to both groups. the implementation of the study will be carried out at the patient's convenience, in a time period that will not interfere with his treatment in any way, and in a special area determined by the hospital management, while preserving his privacy. a mindfullness-based intervention program consisting of 8 sessions will be applied to the intervention group. no intervention will be applied to the control group. at the end of the intervention program, the self-compassion scale and spiritual well-being scale (facit-sp-12) will be administered to both groups.

Eligibility criteria:
inclusion criteria: * women diagnosed with breast cancer, * women who are aware that they have been diagnosed with breast cancer, * women who volunteer to participate in the study, * women over the age of 18 with sufficient communication skills exclusion criteria: * being diagnosed with any mental illness

Keywords: breast cancer minfulness spiritual well-being self-compassion
dorsal scapular nerve injection combined with muscle needle release

Conditions: Dorsal Scapular Nerve Entrapment

Summary: ultrasound-guided perineural injection (pit) of 5% dextrose (d5w) hydrodissection has been widely used in the treatment of peripheral entrapment neuropathies. however, there are few studies investigating the efficacy of pit using d5w hd for dorsal scapular nerve (dsn) entrapment. generally, the dsn entrapment causes the stiffness of the major and minor rhomboideus(2). in clinical practice, the investigators observed that ultrasound-guided pit using d5w hd combined with needle release of major and minor rhomboideus significantly relieved the pain of scapular region. therefore, the investigators aimed to evaluate the 6-month efficacy of this procedure for the participants with dsn entrapment.


Eligibility criteria:
inclusion criteria: * patients with dsn entrapment confirmed by electrophysiological study; * age 18-80 years; * patients who were irresponsive to conservative treatment; * symptoms persisted for more than 3 months. exclusion criteria: * pregnancy * dsn entrapment caused by trauma, surgery or occupying lesions of dsn; * concurrent presence of rheumatic immune diseases, hypothyroidism, or diabetes mellitus; * c5/6 lumbar radiculopathy; * previous history of local injection or surgery for dsn entrapment.
impact of specialised renal care in patients with chronic kidney disease

Conditions: Chronic Kidney Disease

Summary: this is a prospective randomised trial studying patients with stage 3 to 5 chronic kidney disease (ckd) in order to determine the impact of specialised care by nephrologists compared to guidelines-directed management by primary care physicians (pcp) on: a) prognosis (clinical outcome), b) planning of renal replacement therapy (rrt) (urgent versus planned initiation rrt) and c) patient satisfaction.


Eligibility criteria:
inclusion criteria: * patients with ckd stage 3, 4 and 5 (ccl \< 40 ml/min according to abbreviated mdrd formula) aged 18-80 years old and enrolled during a hospitalization. exclusion criteria: * patients previously known by nephrologists. * estimated life expectancy \< 1 year * refusal or inability to sign writing consent

Keywords: chronic kidney disease nephrologists primary care death renal replacement therapy specialised renal care
sildenafil citrate and recurrent abortion

Conditions: Recurrent Abortion

Summary: two groups of unexplained recurrent spontaneous abortion, each included 65 participants. scheduled randomly into; the study group received sildenafil citrate and placebo group. the intervention started from day 21-23 of the cycle preceding spontaneous pregnancy and continued till the 12th-week of gestation. the primary outcome measure was the difference in the live birth between both groups. secondary outcome measures were the differences between both groups regard pulsatility index (pi) and resistance index (ri), a number of take-home babies, the reported side-effects of treatment and the pregnancy-related complications.

two groups of unexplained recurrent spontaneous abortion, each included 65 participants. scheduled randomly into; the study group received sildenafil citrate and placebo group. the intervention started from day 21-23 of the cycle preceding spontaneous pregnancy and continued till the 12th-week of gestation. the primary outcome measure was the difference in the live birth between both groups. secondary outcome measures were the differences between both groups regard pi and ri, a number of take-home babies, the reported side-effects of treatment and the pregnancy-related complications, e.g., preeclampsia and intrauterine growth restriction (\|iugr).

Eligibility criteria:
inclusion criteria: * unexplained recurrent spontaneous abortion. exclusion criteria: * abnormal uterine cavity. * luteal phase insufficiency. * endocrinal disorders, e.g., thyroid diseases, hyperprolactinemia, and diabetes mellitus. * antiphospholipid syndrome. * inherited or acquired thrombophilia. * patients had renal, hepatic or cardiovascular diseases, hypertension, history of smoking, treated with vasodilators or sensitive to or developed severe side-effects with sildenafil citrate.
a study to evaluate the efficacy and safety of hr18042 tablets in the treatment of postoperative pain of impacted tooth.

Conditions: Moderate to Severe Acute Pain

Summary: the purpose of this study was to evaluate the efficacy and safety of hr18042 tablets for the treatment of post-surgical pain after extraction of impacted tooth, find the optimal dose.


Eligibility criteria:
inclusion criteria: 1. 18 to 75 years old. 2. subjects must have a plan of extraction of impacted tooth. 3. subjects with moderate to severe pain (vas score ≥ 50mm).this must be measured within a maximum of 4 hours after the end of extraction of impacted tooth. 4. weight at least 45kg,and no more than 100kg. 5. if a female is of child-bearing potential, she must be using highly effective methods of contraception throughout the study. 6. willingness to comply with the study procedures and requirements. 7. willing and able to provide written informed consent for this study. exclusion criteria: 1. any analgesic medication other than preoperative or intraoperative anaesthetic agents within 12h before taking trial medication medication 2. a longacting nsaid within 4 days,or a shortacting nsaid within 1 days prior to dosing. 3. any anti-depressive medication, selective serotonin reuptake inhibitors (ssris), diet pills et.al. with 30 days of study entry. 4. oral surgical site combined with infection. 5. severe cardiovascular and cerebrovascular diseases. 6. severe gastrointestinal disease. 7. had a history of seizures or drug or alcohol abuse. 8. uncontrolled hypertension. 9. significant abnormal electrocardiogram 10. significant abnormal laboratory value. 11. allergic to the study drug and ingredients. 12. pregnancy, lactation or recent pregnant plan; 13. subjects who participated in a clinical research study involving an experimental drug before 30 days of study entry. 14. other conditions unsuitable for participation in the study.
safety and efficacy study of botulinum toxin type a for the treatment of crow's feet lines and frown lines

Conditions: Facial Rhytides; Crow's Feet Lines; Glabellar Lines

Summary: this study will evaluate the safety and efficacy of botulinum toxin type a compared to placebo for the treatment of crow's feet lines and frown lines (facial rhytides)


Eligibility criteria:
inclusion criteria: * moderate to severe crow's feet lines and frown lines * have adequate vision without the use of eyeglasses to assess facial wrinkles in the mirror (contact lenses ok) exclusion criteria: * current or previous botulinum toxin treatment of any serotype * diagnosis of myasthenia gravis, eaton-lambert syndrome, amyotrophic lateral sclerosis * prior facial cosmetic surgery (e.g., prior periorbital surgery, facial lift, brow lift, eyelid lift or eyebrow surgery) * facial laser or light treatment, microdermabrasion, or superficial peels within 3 months * oral retinoid therapy within one year
use of el-fit app to promote physical activity

Conditions: End Stage Liver DIsease; Cirrhosis, Liver

Summary: transplant-eligible patients with cirrhosis and esld, age 40-70, meld \>/= 10 referred to transplant physical therapy will be invited to participate. the investigators will exclude those who lack a smartphone or the understanding of its functionality, lack home wireless internet, or have recurrent/persistent overt hepatic encephalopathy. following signing of informed consent, each participant will be given a fitbit charge 3 and have el-fit and fitbit apps downloaded to their smartphone. after a brief session with a member of the research team explaining the basic components and functionality of el-fit and fitbit, patients will be provided with general physical activity recommendations (as per our current standard of care) and asked to explore all features of el-fit and fitbit apps, up until their 12-week follow-up visit. phone calls to incentivize physical activity and exercise will be performed by members of the research team.

the study consists of two visits, baseline and 12-week follow-up, with at least one follow-up phone call on a weekly basis. visit one is expected to last for 30 minutes and visit 2 for 60 minutes, whereas each phone call should take no more than 15 minutes. twice during the study period, the investigators will draw serum and plasma samples for future translational research. daily, the physical trainer will review collected data on el-fit research database and fitabase. each participant will have an exit interview by the end of week 12 with the trainer and a member of the research team to talk about their impressions of using el-fit and fitbit, through a structured questionnaire assessing about how user friendly it was to use the el-fit app. finally, trainers will be asked to compare the type of prescription that they provided to patients as part of the standard of care (based on liver frailty index or 6-minute walk test), to compare it with the allocation provided by el-fit stratification algorithm. to learn about how to improve el-fit the investigators will ask patients and their caregivers open-ended questions as part of their exit interview. this will allow us to identify barriers precluding them from keeping up with physical trainer recommendations, and what would they like to include to enhance motivation as part of a physical activity program. a member of the research team will act as a facilitator during this session.

Eligibility criteria:
inclusion criteria: * cirrhosis and esld * transplant eligible * meld \>/=10 * referred to transplant physical therapist exclusion criteria: * those who lack a smartphone or the understanding of its functionality * lack home wireless internet * have recurrent/persistent overt hepatic encephalopathy
triage of patients with acute ischemic stroke due to large vessel occlusions-2

Conditions: Stroke, Acute Ischemic; Endovascular Procedures; Large Vessel Occlusion

Summary: the objective of this study is to create a comprehensive, real-world, multi-center observational registry of consecutive patients admitted to hospitals with acute ischemic stroke (ais) caused by large vessel occlusions (lvo), who are treated with either endovascular therapy (evt) or the best available medical management (bmm).

the track-lvo registry is an observational study conducted across multiple centers with the aim of improving the detection and treatment of large vessel occlusion (lvo) in acute ischemic stroke (ais) patients. lvo is a major predictor of unfavorable outcomes in stroke patients, and the most effective imaging modalities for its detection remain a topic of debate. to address this, the investigators will enroll consecutive ais patients with lvo screened under different imaging modalities and compared the efficacy of endovascular therapy (evt) and best medical management (bmm). the registry defines lvo as an occlusion of the intracranial ica with or without the involvement of the terminal bifurcation, m1 and/or m2 segment of the mca, a1 and/or a2 segment of the aca, va, ba, or p1 and/or p2 segment of the pca. patient information, including basic demographic profiles, imaging characteristics such as volume of ischemic core and occlusion site, and treatment-related complications will be collected for both evt and bmm groups. for patients in the evt group, detailed information on the evt procedure and angiographic images will also be collected. the study aims to identify the optimal imaging modalities for lvo detection and to compare the prognosis of ais patients with lvo receiving evt versus bmm. this academic, real-world, multi-center, observational registry will contribute valuable insights to improve the detection and treatment of lvo in ais patients, ultimately improving patient outcomes and reducing the burden of stroke on public health and socio-economic development.

Eligibility criteria:
inclusion criteria: 1. patient admitted from jan. 1st 2018 to jan. 1st 2028; 2. age ≥ 18; 3. ischemic stroke confirmed by head ct or mri; 4. large vessel occlusion confirmed by head cta or mra: intracranial internal carotid artery (ica), middle cerebral artery (mca m1/m2), anterior cerebral artery (aca a1/a2), basilar artery (ba), vertebral artery (va), and posterior cerebral artery (pca p1/p2); 5. patients receiving either endovascular therapy or best medical treatment; exclusion criteria: - none

Keywords: acute ischemic stroke endovascular therapy large vessel occlusion
pulse oximetry_performance testing- pcba-1 (printed circuit board assembly)

Conditions: Healthy

Summary: to determine accuracy specifications of the pulse oximeter.


Eligibility criteria:
inclusion criteria: 1. male or female subjects between the ages of 18 to 50 years (inclusive). 2. must undergo a physical examination by a licensed physician, advanced practice nurse or physician assistant, including a 12 lead ecg, a medical history, and a blood test checking complete blood count and screening for sickle cell trait or disease 3. all female volunteers must have a negative urine pregnancy test prior to participation. exclusion criteria: 1. pregnancy or lactating women 2. unexplained syncopal episodes 3. hypertension (defined as a systolic pressure of \>145 mmhg or a diastolic pressure \>90 mm hg on three consecutive readings) 4. premature ventricular contractions (pvc's) that are symptomatic or occur at a rate of more than 5/minute 5. history of seizures (except childhood febrile seizures) or epilepsy 6. routine use of tranquilizers and/or excessive anxiety 7. history of frequent headaches or migraines 8. history of stroke 9. previous injury or trauma to fingers or hands that may change blood flow or vascular supply and affect our ability to test multiple sensors 10. history of "altitude sickness" defined as headaches, malaise or dizziness when in the mountains or in an aircraft at altitude significantly above sea level for a prolonged period of time (\> 1 hour) 11. history of significant respiratory disease, such as severe asthma, emphysema, etc. 12. sickle cell disease or trait. 13. the use of medications, pre-existing medical conditions, treatment for a medical condition or any other reason deemed relevant by the clinician conducting the study. 14. abnormal ecg finding 15. prior or known allergies to lidocaine (or similar pharmacologic agents, e.g., novocain) 16. prior or known allergies to heparin. 17. history of transient ischemic attacks or carotid artery disease 18. history of myocardial ischemia, angina, myocardial infarction, congestive heart failure or cardiomyopathy 19. history of chronic renal impairment 20. history of recent arterial cannulation (less than 1 month prior to study) 21. history of complications from previous arterial cannulation 22. current use of blood thinners

Keywords: subjects
skin-to-skin contact with a sling in primipar mothers who delivered by cesarean section

Conditions: Breast Feeding; Caesarean Section;Stillbirth

Summary: the first hours after birth are critical for the physiological and psychological adaptation process of the newborn from intrauterine to extrauterine life. the world health organization (who) recommends skin-to-skin contact as a routine part of care to stabilize the newborn's vital signs and strengthen the mother-infant bond. however, the rate of skin-to-skin contact in women who give birth by cesarean section is lower compared to vaginal deliveries. considering the global increase in cesarean birth rates, it is necessary to develop appropriate and practical care methods for mothers and newborns who deliver by cesarean section. the literature has examined the effects of the duration of skin-to-skin contact on breastfeeding initiation, neonatal hypothermia, and cardiopulmonary stability. however, studies aimed at increasing the duration of skin-to-skin contact are limited. this study compares the effects of standard skin-to-skin contact and skin-to-skin contact using a sling on the duration of skin-to-skin contact, postpartum breastfeeding success, and physiological weight loss of the newborn in primiparous mothers who delivered by cesarean section.


Eligibility criteria:
inclusion criteria: * healthy mothers who gave birth by cesarean section * primiparous mothers * healthy newborns exclusion criteria: * mothers who gave birth vaginally * newborns using formula milk * mothers with breastfeeding difficulties * preterm newborns * multiple births * mothers and newborns with unstable health conditions

Keywords: skin-to-skin contact caesarean section breastfeeding success newborn physiological weight loss sling
core temperature afterdrop in cold-water swimming

Conditions: Hypothermia, Accidental; Cold Water Swimming

Summary: a significant risk associated with hypothermia during exercise in a cold environment is the core temperature (t°core) afterdrop, which corresponds to a continuous fall in t°core during rewarming after hypothermia. however, the rate and predictors of the afterdrop are unclear, particularly during prolonged cold water swimming. the investigators propose to measure the changes in t°core during and after a cold water swim at 12.5-13°c qualifying for english channel swim and to test the impact of anthropometric and swimming parameters on the duration of the t°core afterdrop. the hypotheses are that afterdrop is common during a prolonged cold water swimming event and that protective factors against t°core drop during cold water swimming (increased body fat and bmi) might, conversely, be associated with prolonged afterdrop.


Eligibility criteria:
inclusion criteria: * swimmers taking part in the channel swim camp * swimmers above 18 years of age * swimmers willing and able to give informed consent for participation in the study exclusion criteria: * swallowing disorder * chronic gastrointestinal disease * mri scheduled within 48 hours after the race.
misoprostol for cervical priming prior to vacuum aspiration

Conditions: First Trimester Pregnancy; Surgical Termination of Pregnancy

Summary: despite of the widespread use, and extensive studies, the optimal route of administration of misoprostol before surgical abortion remains to be defined. following administration of 400 mcg vaginally as per clinical guidelines, the time for optimal priming seems to be 3 hours, but the longer the interval the greater the risk or bleeding and expulsion of the uterine contents before the surgical evacuation. sublingual administration seems to give adequate plasma concentration and cervical priming faster than oral or vaginal administration. this may allow a shorter waiting time with maintained efficacy, less side effects and logistic advantages.


Eligibility criteria:
inclusion criteria: * women opting for first trimester surgical abortion * nulliparous * able and willing to provide informed consent exclusion criteria: * unwilling to participate, * unable to communicate in swedish and english and * minors (i.e. women \< 18 years of age), * contraindications to misoprostol * women with pathological pregnancies

Keywords: misoprostol first trimester pregnancy surgical abortion cervical priming
effect of acetazolamide on diuresis and natriuresis in patients with acute heart failure (sandi study)

Conditions: Heart Failure; Persistent Congestion

Summary: the goal of this observational study is to assess the natriuretic effect of intravenous acetazolamide in patients admitted with heart failure and persistent congestion despite treatment with intravenous furosemide and sodium-glucose cotransporter type 2 (isglt2) inhibitors. the main question it aims to answer is whether there is a difference in natriuresis 48 hours after acetazolamide association to medical treatment recommended by the guidelines (furosemide and isglt2).


Eligibility criteria:
inclusion criteria: * patients admitted for acute heart failure and ≥ 1 clinical sign of volume overload (edema, ascites, or pleural effusion). * ntprobnp levels \>1000 pg/ml or bnp \>250 ng/ml on admission. * under treatment with furosemide and isglt2 according to european guidelines and indication of association of another diuretic due to residual congestion data defined by advor score\>1. exclusion criteria: * systolic blood pressure \<90 mmhg or mean arterial pressure \< 65 mmhg. * maintenance treatment with acetazolamide/ treatment with acetazolamide in the month prior to inclusion in the study. * anticipated need for intravenous inotropes, vasopressors or nitroprusside during the study. * contraindication to isglt2. * type 1 diabetes mellitus * gfr \< 20 ml/min/m2 or renal replacement therapy/ultrafiltration at any time prior to the study. * anticipated exposure to nephrotoxic agents, such as iodinated contrast during admission. * concurrent diagnosis of acute coronary syndrome. * history of congenital heart disease requiring surgical correction. * history of cardiac transplantation and/or ventricular assist device. * pregnant or breastfeeding patients. * inability to adequately collect diuresis. * serum potassium less than 3.5 meq/l. * venous ph \<7.30 * severe aortic stenosis or obstructive hypertrophic cardiomyopathy. * sulfonamide allergy, liver cirrhosis, renal lithiasis.

Keywords: acetazolamide